Canada
· Delayed Price · Currency is CAD Crescita Therapeutics Statistics
Total Valuation
Crescita Therapeutics has a market cap or net worth of CAD 12.40 million. The enterprise value is 4.43 million.
| Market Cap | 12.40M |
| Enterprise Value | 4.43M |
Important Dates
The next estimated earnings date is Thursday, August 22, 2024.
| Earnings Date | Aug 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Crescita Therapeutics has 19.38 million shares outstanding. The number of shares has decreased by -4.26% in one year.
| Shares Outstanding | 19.38M |
| Shares Change (YoY) | -4.26% |
| Shares Change (QoQ) | -0.76% |
| Owned by Insiders (%) | 12.29% |
| Owned by Institutions (%) | n/a |
| Float | 17.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.75 |
| PB Ratio | 0.72 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.48 |
| EV / Sales | 0.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.30 |
Financial Position
The company has a current ratio of 3.37, with a Debt / Equity ratio of 6.03.
| Current Ratio | 3.37 |
| Quick Ratio | 2.23 |
| Debt / Equity | 6.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.05 |
| Interest Coverage | -43.01 |
Financial Efficiency
Return on equity (ROE) is -15.79% and return on invested capital (ROIC) is -10.16%.
| Return on Equity (ROE) | -15.79% |
| Return on Assets (ROA) | -8.26% |
| Return on Capital (ROIC) | -10.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.68 |
| Inventory Turnover | 1.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.70% in the last 52 weeks. The beta is 1.71, so Crescita Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -8.70% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 0.49 |
| Relative Strength Index (RSI) | 61.70 |
| Average Volume (20 Days) | 14,306 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Crescita Therapeutics had revenue of CAD 16.84 million and -2.98 million in losses. Loss per share was -0.15.
| Revenue | 16.84M |
| Gross Profit | 9.21M |
| Operating Income | -3.27M |
| Pretax Income | -2.79M |
| Net Income | -2.98M |
| EBITDA | -2.23M |
| EBIT | -3.27M |
| Loss Per Share | -0.15 |
Balance Sheet
The company has 9.01 million in cash and 1.04 million in debt, giving a net cash position of 7.98 million or 0.41 per share.
| Cash & Cash Equivalents | 9.01M |
| Total Debt | 1.04M |
| Net Cash | 7.98M |
| Net Cash Per Share | 0.41 |
| Equity (Book Value) | 17.20M |
| Book Value Per Share | 0.89 |
| Working Capital | 11.97M |
Cash Flow
In the last 12 months, operating cash flow was 789,000 and capital expenditures -1.05 million, giving a free cash flow of -256,000.
| Operating Cash Flow | 789,000 |
| Capital Expenditures | -1.05M |
| Free Cash Flow | -256,000 |
| FCF Per Share | -0.01 |
Margins
Gross margin is 54.66%, with operating and profit margins of -19.41% and -17.72%.
| Gross Margin | 54.66% |
| Operating Margin | -19.41% |
| Pretax Margin | -16.55% |
| Profit Margin | -17.72% |
| EBITDA Margin | -13.25% |
| EBIT Margin | -19.41% |
| FCF Margin | -1.52% |
Dividends & Yields
Crescita Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.26% |
| Shareholder Yield | 4.26% |
| Earnings Yield | -23.49% |
| FCF Yield | -2.06% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |